Developing alternative routes of immunotherapies with innovative drugs for neurodegenerative diseases.

Learn more about Tiziana   Tiziana Investor Deck   Scientific Presentations and Updates

In the Media

Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology

11 April 2024

NEW YORK, April 11, 2024 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced an upcoming oral presentation, titled, “Treatment of PIRA with Nasal Foralumab Dampens Microglial Activation...

Read more

Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease

05 March 2024

  • Data shows reduction of microglia activation and improvement in behavior in rodent models of Alzheimer’s disease (AD) and Parkinson’s disease (PD)
  • Nasal anti-CD3 reduced hemorrhage and edema...
Read more

Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients

08 January 2024

NEW YORK, January 08, 2024 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced positive findings have been seen in a total of six out of eight Intermediate...

Read more

Our Mission

Our mission is to bring breakthrough therapies to patients with the aim of treating Secondary Progressive Multiple Sclerosis, ALS, Alzheimer's, and other CNS indications. Crohn's Disease, lung diseases and optimizing health outcomes.

Learn more

Clinical Candidates

Our major clinical assets are supported by extensive worldwide issued patents and pending patent applications covering composition of matter, formulation technologies, manufacturing processes and disease indications.



Foralumab is a fully human anti-CD3 monoclonal antibody (mAb) for treatment of Crohn’ s Disease and neurodegenerative indications.

Learn more about Foralumab

Anti IL-6 Receptor mAb

We are developing a fully human monoclonal antibody (mAb) targeting the receptor for IL-6 as a potential treatment for lung diseases.

Learn more about Anti IL-6R


Milciclib is the Company’s clinical candidate for the treatment in cancer indications. The company is exploring the combination of milciclib and gemcitibine in NSCLC patients with pan KRAS+ mutations.

Learn more about Milciclib

Clinical Trials

Tiziana is currently conducting clinical development programs for Foralumab, Anti IL-6R and Milciclib


Tiziana reported positive clinical data in a Phase I clinical trial of nasally-dosed Foralumab in healthy subjects in collaboration with Dr. Howard Weiner at Brigham and Women’s Hospital in Boston. Expanded Access program now dosing 6 patients. Phase 2 patient enrollment is expected to begin in 2H 2023 for nasally administered Foralumab for the treatment of Non-active, Secondary Progressive, Multiple Sclerosis.

See more Foralumab clinical trials

Anti IL-6R mAb (TZLS-501)

Manufacturing of clinical supplies for a Phase 1 study is anticipated to be completed in 4Q 2022.


We are exploring a study to evaluate the combination of milciclib and gemcitabine in NSCLC subjects with associated pan KRAS-positive mutations.

See more Milciclib clinical trials

Tiziana Life Sciences is listed on NASDAQ